COVID-19 Central Research Database
592 items found for ""
- Teenager Develops Possible Treatment ... Awarded $25,000!!!
A teenage girl in Texas is getting national recognition for her work on a potential treatment for COVID-19 ... and she's already getting paid. Anika Chebrolu, a 14-year-old freshman at Independence High School in Frisco, is being hailed as the country's top young scientist ... and she won $25,000 for her potential coronavirus breakthrough. Anika won the 3M Young Scientist Challenge for her hard work identifying a potential drug to treat COVID-19. The brilliant student says she developed -- while in the 8th grade -- a molecule that binds to a protein on the SARS-CoV-2 virus, and essentially stops the virus from functioning. A brilliant discovery for an adult, much less a kid. This part will blow your mind, unless you're a scientist -- Anika says she started with a database of over 682 million compounds and used a few computer programs to figure out how and where the molecule would bind to the virus. We'll take her word for it. Anika was still in middle school when she entered the contest and was initially planning her science project around finding ways to combat seasonal flu. But, like many pro scientists, she pivoted when the pandemic hit. She says she drew inspiration from stories about people suffering from COVID-19 ... and she's also crediting her grandpa, a chemistry professor, for steering her toward science. Ref Credit and Sourc of Information https://www.tmz.com/2020/10/16/texas-teen-wins-prize-developing-potential-covid-19-treatment/?fbclid=IwAR1EmjgC_3JcxgMWjFeu7rn_BgjAPY4Nr2cH3V8jwir6zUqxRg_pEwdnI7E
- Diagnosis process of Covid-19 : How to Obtain a Nasopharyngeal Swab Specimen
Collection of specimens from the surface of the respiratory mucosa with nasopharyngeal swabs is a procedure used for the diagnosis of Covid-19 in adults and children.1-4 The procedure is also commonly used to evaluate patients with suspected respiratory infection caused by other viruses and some bacteria. This video describes the collection of nasopharyngeal specimens for detection of Covid-19, the illness caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are no specific contraindications for collecting specimens with nasopharyngeal swabs. However, clinicians should be cautious if the patient has had recent nasal trauma or surgery, has a markedly deviated nasal septum, or has a history of chronically blocked nasal passages or severe coagulopathy. Preparation and Equipment Nasopharyngeal swabs are specifically manufactured to have long, flexible shafts made of plastic or metal and tips made of polyester, rayon, or flocked nylon. In addition to nasopharyngeal swabs, you will need personal protective equipment (PPE), including a gown, nonsterile gloves, a protective mask, and a face shield, as described below. Make sure that all sample tubes have been labeled and that the appropriate requisition forms have been filled out before starting the procedure. Figure 1. Personal Protective Equipment.It is essential that you follow the pertinent respiratory and contact precautions specified by the Centers for Disease Control and Prevention (CDC) and by your own institution and that you put on the PPE correctly (Figure 1). If possible, you should put on and take off the PPE in the presence of an observer to make sure there are no breaks in technique that may pose a risk of contamination. First, put on a protective gown, wash your hands with soap and water (or use an alcohol-based solution), and put on a pair of nonsterile gloves. Then put on a protective mask with a rating of N95 or higher, as recommended by the CDC. Finally, put on a face shield for face and eye protection. Procedure Figure 2. Patient Wearing a Mask.Figure 3. Obtaining the Nasopharyngeal Swab Specimen.Masks are recommended for all patients suspected of having Covid-19 (Figure 2). Ask the patient to take off her mask and blow her nose into a tissue to clear excess secretions from the nasal passages. Remove the swab from the packaging. Tilt the patient’s head back slightly, so that the nasal passages become more accessible. Ask the patient to close her eyes to lessen the mild discomfort of the procedure. Gently insert the swab along the nasal septum, just above the floor of the nasal passage, to the nasopharynx, until resistance is felt (Figure 3). Insert the swab into the nostril, parallel to the palate. If you detect resistance to the passage of the swab, back off and try reinserting it at a different angle, closer to the floor of the nasal canal. The swab should reach a depth equal to the distance from the nostrils to the outer opening of the ear. The CDC recommends leaving the swab in place for several seconds to absorb secretions and then slowly removing the swab while rotating it. Your institution may also recommend rotating the swab in place several times before removing it. Ask the patient to reapply her mask. Handling of the Specimen Figure 4. Handling the Nasopharyngeal Swab Specimen.Open the collection tube and insert the swab into the tube. Break the swab at the groove and discard what remains of the swab. Close the labeled collection tube, wipe the tube with a surface-disinfectant wipe, and insert the tube into an open biohazard bag held by an assistant (Figure 4). Depending on institutional practices, you may instead return the sample to its original packaging for transport. Follow the CDC directions for direct processing of the swab specimen or placement of the swab in media with or without refrigeration. Removing Personal Protective Equipment Remove your PPE as shown in the video and described here or in accordance with the standards at your institution. First, remove your gown and gloves. Clean your hands with an alcohol-based solution or soap and water. Put on a new pair of gloves, and then remove your face shield and either dispose of it or clean and store it in accordance with the guidelines at your institution. Remove your gloves, rewash your hands, and put on another pair of gloves; then remove your mask and follow your institutional guidelines for disposal or reuse. Finally, remove the last pair of gloves and wash your hands. Summary This video demonstrates the collection of specimens from the surface of the respiratory mucosa with nasopharyngeal swabs for the diagnosis of Covid-19 in adults and in children. It is important to use approved PPE and the appropriate technique to minimize the possibility of spreading the virus. Ref Credit and Source of Information https://www.nejm.org/doi/full/10.1056/NEJMvcm2010260?query=featured_coronavirus
- SARS-CoV-2 surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change
Mycroft-West et al. (2020)Running title: SARS-CoV-2 surface S1 Receptor Binding Domain binds heparinThe 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding Many pathogens take advantage of the dependence of the host on the interaction of hundreds of extracellular proteins w/the glycosaminoglycans heparan sulphate to regulate homeostasis and use heparan sulphate as a means to adhere & gain access to cells. Moreover, mucosal epithelia such as that of the respiratory tract are protected by a layer of mucin polysaccharides, which are usually sulphated. The polydisperse, natural products of heparan sulphate and the allied polysaccharide,heparin have been found to be involved & prevent infection by a range of viruses including S-associated coronavirus strain HSR1.Here we use surface plasmon resonance & circular dichroism to measure the interaction between the SARS-CoV- 2 Spike S1 protein RBD (#SARS_CoV_2_S1_RBD)& #heparin. The data demonstrate an interaction between the recombinant surface receptor binding domain & polysaccharide. This has implications for the rapid development of a first-line therapeutic by repurposing heparin and for next-generation,tailor-made,GAG-based antivirals. Ref Source of Information https://www.biorxiv.org/content/10.1101/2020.02.29.971093v2.full.pdf
- Discussion Forum | Corona ResearchGate
To see this working, head to your live site. All Posts My Posts Login / Sign up Business Forum Explore the forum below to find answers to all of you business related questions and concerns. Sort by: Recent Activity Create New Post Unknown member whatsapp@ +27 63 409 6205 psychic bring back lost lover spells ex in New York Albany Buffalo Rochester Syracuse Niagara Falls Utica Upon completion of the spell work, which requires several extensive ritual sessions, a talisman is prepared for you. Psychic sheik fahad is your answer. Spell Casting love binding spells bring back Lost Lover Spells Divorce Spells https://goo Views 0 comments 0 0 Recent Activity: Nov 23 Unknown member whatsapp@ +27 63 409 6205 psychic bring back lost lover spells ex in Valley Renton Federal Way Yakima Bellingham Kirkland Auburn Upon completion of the spell work, which requires several extensive ritual sessions, a talisman is prepared for you. Psychic sheik fahad is your answer. Spell Casting love binding spells bring back Lost Lover Spells Divorce Spells https://goo Views 0 comments 0 0 Recent Activity: Nov 23 Unknown member whatsapp@ +27 63 4096205 psychic bring back lost lover spells ex in benoni centurion midrand fourways vanderbijlpark krugersdorp randfontein Upon completion of the spell work, which requires several extensive ritual sessions, a talisman is prepared for you. Psychic sheik fahad is your answer. Spell Casting love binding spells bring back Lost Lover Spells Divorce Spells https://goo Views 0 comments 0 0 Recent Activity: Nov 23 Vivian Creative SARS-CoV-2 Therapeutic Human mAb Strategies to Develop Therapeutic Human Monoclonal Antibodies Against SARS-CoV-2 Currently, there are two main technical solutions for the development of therapeutic human monoclonal antibodies to COVID-19. Therapeutic Human Monoclonal Antibodies from COVID-19 Recovered Patient Sera At present, som Views 0 comments 0 0 Recent Activity: Nov 02 Vivian Creative siRNA for the Treatment of SARS-CoV-2 RNA interference in animals is mediated by small double-stranded RNA molecules, siRNA. siRNAs can be used as tools to study single gene function both in vivo and in vitro and are an attractive new class of therapeutics. The siRNA delivery systems are categorized as viral delivery systems and non Views 0 comments 0 1 Recent Activity: Oct 07 Vivian Creative In Silico Vaccine Design for SARS-CoV-2 The current outbreak of SARS-CoV-2 in China and its subsequent spread to many countries around the world pose a huge threat to global public health, and no vaccine has yet been approved to prevent the disease. Therefore, the development of safe and effective vaccines is very important for controllin Views 0 comments 0 1 Recent Activity: Aug 16 Vivian Creative Protease Inhibitors for the Treatment of SARS-CoV-2 Since December 2019, a series of unexplained pneumonia cases have occurred in Wuhan, China. Genome sequencing of these patient samples confirmed that the culprit for these infections was beta-coronavirus, which had never been reported before, and was later named SARS-CoV-2. So far, the infection has Views 0 comments 0 0 Recent Activity: Aug 04 Vivian Creative Aptamers to SARS-CoV-2 Spike and N Protein Since the outbreak of the new coronavirus pneumonia COVID-19 caused by the SARS-CoV-2, the disease has spread rapidly around the world. Considering the potential threat of the COVID-19 pandemic, scientists around the world have been working hard to understand this new virus and its pathophysiology t Views 0 comments 0 0 Recent Activity: Jul 03 Dinakaran Pannerselvam Identified from SARS-CoV-2 as Immune Targets for Pre-Emptive Pan-Coronavirus Vaccines Over the last two decades, there have been three deadly human outbreaks of Coronaviruses (CoVs) caused by emerging zoonotic CoVs: SARS-CoV, MERS-CoV, and the latest highly transmissible and deadly SARS-CoV-2, which has caused the current COVID-19 global pandemic. All three deadly CoVs originated fro Views 1 comment 1 1 Recent Activity: Jun 06 Vivian Creative Antiviral Drug Discovery for SARS-CoV-2 A novel coronavirus (SARS-CoV-2) originally detected in Wuhan, China, has caused an outbreak of viral pneumonia spreading to all provinces of China and lots of countries. Unprecedented efforts and dedication have been devoted to developing effective antiviral drugs to defeat this deadly infectious d Views 0 comments 0 0 Recent Activity: May 05 Dinakaran Pannerselvam Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection Serum samples obtained from unvaccinated persons after infection with the B.1.1.7 (alpha), B.1.351 (beta), or B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been shown to neutralize the B.1.1.529 (omicron) variant only occasionally. 1 Similarly, level Views 0 comments 0 0 Recent Activity: Mar 24 Vivian Creative SARS-CoV-2 (COVID-19) Related Detection Kits Creative Biolabs is an industry leading supplier of recombinant proteins, antibodies, and kits. In response to the global epidemic of COVID-19, Creative Biolabs has quickly integrated its strengths to offer related proteins, antibodies, and kit products, and provide various SARS-CoV-2 (COVID-19) re Views 0 comments 0 0 Recent Activity: Mar 15 Dinakaran Pannerselvam Neocov - Close relatives of MERS-CoV in bats use ACE2 as their functional receptor | New Variant Middle East Respiratory Syndrome coronavirus (MERS-CoV) and several bat coronaviruses employ Dipeptidyl peptidase-4 (DPP4) as their functional receptors 1 – 4 . However, the receptor for NeoCoV, the closest MERS-CoV relative yet discovered in bats, remains enigmatic 5 . In this study, we unexpectedl Views 0 comments 0 0 Recent Activity: Jan 29 Dinakaran Pannerselvam Persistent SARS-CoV-2 Nucleocapsid Protein Presence in the Intestinal Epithelium of a Pediatric Patient 3 Months After Acute Infection In addition to the severe impact of acute respiratory disease during the SARS-CoV-2 pandemic, the issue of “Long COVID” illness has impacted large numbers of patients following the initial infection. Wide ranges of Long Covid incidence have been reported, ranging from 30 to 87%. Long COVID has a var Views 0 comments 0 0 Recent Activity: Jan 26 Dinakaran Pannerselvam Omicron blindspots: why it’s hard to track coronavirus variants Researchers are racing to detect Omicron, the latest SARS-CoV-2 variant of concern, by sequencing the genomes of coronaviruses infecting people. But surveillance through genomic sequencing can be slow and patchy, complicating the picture of how and where Omicron spreads. One positive development is Views 1 comment 1 1 Recent Activity: Jan 17 Unknown member whatsapp@ +27 63 409 6205 psychic bring back lost lover spells ex in Utica Yonkers Ithaca Binghamton Poughkeepsie Newburgh White Plains Upon completion of the spell work, which requires several extensive ritual sessions, a talisman is prepared for you. Psychic sheik fahad is your answer. Spell Casting love binding spells bring back Lost Lover Spells Divorce Spells https://goo Views 0 comments 0 0 Recent Activity: Nov 23 Unknown member whatsapp@ +27 63 409 6205 psychic bring back lost lover spells ex in Seattle Spokane Tacoma Vancouver Bellevue Kent Everett Spokane Upon completion of the spell work, which requires several extensive ritual sessions, a talisman is prepared for you. Psychic sheik fahad is your answer. Spell Casting love binding spells bring back Lost Lover Spells Divorce Spells https://goo Views 0 comments 0 0 Recent Activity: Nov 23 Unknown member whatsapp@ +27 63 409 6205 psychic bring back lost lover spells ex in johannesburg pretoria cape town sandton kempton park boksburg Upon completion of the spell work, which requires several extensive ritual sessions, a talisman is prepared for you. Psychic sheik fahad is your answer. Spell Casting love binding spells bring back Lost Lover Spells Divorce Spells https://goo Views 0 comments 0 0 Recent Activity: Nov 23 Vivian Creative SARS-CoV-2 Vaccine Creative Biolabs is dedicated to discovering and developing vaccines against SARS-CoV-2 diseases and other emerging infectious diseases. Our vaccine discovery and development-related services provide cutting-edge technical support to accelerate vaccine research from the identification of potential Views 0 comments 0 0 Recent Activity: Nov 02 Vivian Creative VLPs Based Vaccine VLPs are multi-protein structures, which mimic the organization and conformation of authentic native viruses, but lack the viral genome, and may produce safer and cheaper vaccine candidates. If the specific native viral proteins with immunosuppressive function are excluded from VLPs, the efficacy of Views 0 comments 0 1 Recent Activity: Oct 07 Vivian Creative Vaccine Discovery Services for SARS-CoV-2 Vaccine research and development has become very urgent with the emergence of new diseases, increased burden of infectious disease, and growing concern regarding vaccine safety. Creative Biolabs has more than a decade of experience and deep expertise in vaccine discovery and development, and we ar Views 0 comments 0 1 Recent Activity: Aug 16 Vivian Creative Antisense Oligonucleotides as a Candidate for SARS-CoV-2 Antiviral Drug Most drugs for COVID-19 are based on inhibiting the interaction of SARS-CoV-2 with the host cell membrane to prevent the virus from entering the cell, or based on disrupting the virus component, but because the virus has the ability to mutate to escape the body's immune system monitoring, these stra Views 0 comments 0 0 Recent Activity: Aug 04 Vivian Creative Complement Therapy for COVID-19 The world-leading-CRO Creative Biolabs has a well-known reputation for its professionalism in development services of complement therapy. To defeat flood-spreading COVID-19 epidemic, we are innovatively putting an eye on the potential of complement therapy. Inflammatory Factor Storm and SARS-CoV-2 Views 0 comments 0 0 Recent Activity: Jul 03 Vivian Creative Evaluation Platforms for SARS-CoV-2 Drugs Creative Biolabs is always dedicated to assisting our clients with the most satisfactory drug discovery related services. In response to the increasingly severe SARS-CoV-2 infection situation, we can not only provide super high-quality data but also help you establish a proteomics research pipeline Views 0 comments 0 1 Recent Activity: Jun 06 Dinakaran Pannerselvam Intersecting pandemics of tuberculosis & COVID-19: population-level & patient-level impact, clinical presentation, & correctiveinterventions The aim of this Series paper is to review the interactions between COVID-19 and tuberculosis, including the population-level impact of COVID-19 on tuberculosis outcomes, the clinical presentation and diagnosis of tuberculosis–COVID-19 co-infection, the patient-level impact of COVID-19 on the managem Views 0 comments 0 0 Recent Activity: Mar 24 Dinakaran Pannerselvam SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study Background The memory immune response is crucial for preventing reinfection or reducing disease severity. However, the robustness and functionality of the humoral and T-cell response to SARS-CoV-2 remains unknown 12 months after initial infection. The aim of this study is to investigate the durabili Views 0 comments 0 0 Recent Activity: Mar 24 Dinakaran Pannerselvam Protection against the Omicron Variant from Previous SARS-CoV-2 Infection Natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits strong protection against reinfection with the B.1.1.7 (alpha) , B.1.351 (beta),and B.1.617.2 (delta) variants. However, the B.1.1.529 (omicron) variant harbors multiple mutations that can mediate immune evas Views 0 comments 0 0 Recent Activity: Feb 26 Dinakaran Pannerselvam Nervous system consequences of COVID-19 Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is considered a respiratory pathogen, myriad neurologic complications—including confusion, stroke, and neuromuscular disorders—manifest during acute COVID-19. Furthermore, maladies such as impaired concentration, headache, sensory Views 0 comments 0 0 Recent Activity: Jan 27 Vivian Creative SARS-CoV-2 Spike-pseudovirus Based Neutralization Assay Pseudovirus’ Role in Evaluating Vaccine / Drug Neutralization Ability The ability of vaccines or drugs to neutralize viruses is an important sign of their efficacy in preventing or treating viral diseases. Under normal circumstances, the vaccine or drug can be directly incubated with live virus in Views 0 comments 0 0 Recent Activity: Jan 17 Vivian Creative Vaccine Discovery Services for SARS-CoV-2 Vaccine research and development has become very urgent with the emergence of new diseases, increased burden of infectious disease, and growing concern regarding vaccine safety. Creative Biolabs has more than a decade of experience and deep expertise in vaccine discovery and development, and we ar Views 0 comments 0 2 Recent Activity: Dec 17, 2021 Forum - Frameless
- Potential effects of curcumin in the treatment of COVID-19 infectionIn Research Forum·June 29, 2020The main clinical manifestation of COVID-19 is the presence of respiratory symptoms, but some patients develop severe cardiovascular and renal complications. There is an urgency to understand the mechanism by which this virus causes complications so as to develop treatment options. Curcumin, a natural polyphenolic compound, could be a potential treatment option for patients with coronavirus disease. In this study, we review some of the potential effects of curcumin such as inhibiting the entry of virus to the cell, inhibiting encapsulation of the virus and viral protease, as well as modulating various cellular signaling pathways. This review provides a basis for further research and development of clinical applications of curcumin for the treatment of newly emerged SARS-CoV-2. CONCLUSION AND CHALLENGES In this review, we have attempted an overview of the potential antiviral effects of curcumin that can be helpful for researchers to further investigate the potency of curcumin against the new emerging SARSCoV-2 infection. The ability of curcumin to modulate a wide range of molecular targets makes it a suitable candidate for the management of coronavirus infection. Curcumin may have beneficial effects against COVID-19 infection via its ability to modulate the various molecular targets that contribute to the attachment and internalization of SARS-CoV-2 in many organs, including the liver, cardiovascular system, and kidney. Curcumin could also modulate cellular signaling pathways such as inflammation, apoptosis, and RNA replication. Curcumin may also suppress pulmonary edema and fibrosis-associated pathways in COVID-19 infection. Despite the potential beneficial effects and safety profile of curcumin against various diseases, the limited bioavailability of this turmericderived compound, especially via oral administration may be a problematic issue (Anand, Kunnumakkara, Newman, & Aggarwal, 2007). Yang et al. demonstrated that intravenous administration of curcumin (10 mg/kg) resulted in better bioavailability in comparison to oral administration with a higher dose (500 mg/kg) (K. Y. Yang, Lin, Tseng, Wang, & Tsai, 2007). Several clinical trials have shown that the issue regarding the bioavailability of curcumin can be mitigated by administering higher concentrations within non-toxic limits (Kunnumakkara et al., 2019). In addition, many studies have suggested various ways to improve the bioavailability of curcumin such as manipulation and encapsulation of curcumin into micelles, liposomes, phospholipid complexes, exosomes, or polymeric nanocarrier formulation and also utilization of curcumin in combination with cellulosic derivatives, natural antioxidants, and a hydrophilic carrier (Jäger et al., 2014; Moballegh Nasery et al., 2020). Moreover, several studies have reported the synergistic therapeutic effects of curcumin in combination with other natural or synthetic compounds (Singh et al., 2013). Overall, the welldocumented anti-inflammatory and immunomodulatory effects of curcumin along with the evidence on the anti-fibrotic and pulmonoprotective effects of this phytochemical on the lung tissue make it a promising candidate for the treatment of COVID-19. Since curcumin is known to have strong inhibitory effects on NF-κB and several pro-inflammatory cytokines, it can be particularly helpful as an adjunct in reversing the fatal cytokine storm that occurs in serious cases of COVID-19. 6 ZAHEDIPOUR ET AL. To sum up, this review shows that curcumin as an antiviral and anti-inflammatory agent can be helpful for both prevention and treatment of new emerging coronavirus. However, well-designed clinical trials are needed to demonstrate the potential efficacy of curcumin against SARS-CoV-2 infection and its ensuing complications. Reference & Source Information: https://onlinelibrary.wiley.com/ Read more on :2561
- Vaccine For Coronavirus Likely to be Available by September, Says Oxford Expert Sarah GilbertIn Research Forum·April 15, 2020Professor Sarah Gilbert, an expert of mediconology at the University of Oxford, said she is confident of a vaccine for novel coronavirus being available by September this year. Her claims comes in contradiction of most pharmaceutical wizards predicting an 18-month time frame to find either a vaccine or a cure to the COVID-19 disease. COVID-19 Ten Times Worse Than Swine Flu, Vaccine Needed to Fully Halt Disease: WHO.Londo: Professor Sarah Gilbert, an expert of mediconology at the University of Oxford, said she is confident of a vaccine for novel coronavirus being available by September this year. Her claims comes in contradiction of most pharmaceutical wizards predicting an 18-month time frame to find either a vaccine or a cure to the COVID-19 disease. COVID-19 Ten Times Worse Than Swine Flu, Vaccine Needed to Fully Halt Disease: WHO. Gilbert, while speaking to BBC Radio on Monday, said trials are being conducted across the world at an "unprecedented rate". In the University of Oxford as well, the process to screen over 500 volunteers - aged between 18 to 55 - for the ChAdOx1 nCoV-19 vaccine has been expedited, she said. The manufacturers should be ready to produce the vaccine in bulk, she said, adding that billions across the globe would have to be vaccinated against the disease. The process to initiate manufacturing should not be kept on hold till the vaccine is confirmed to be successful, the professor added. "We need to start manufacturing large amounts of the vaccine. It is not uncommon for companies to start manufacturing a new vaccine before they really know for certain it works”, she told the radio channel during the morning show. The Oxford team, which was successful with its rapid vaccine response tests for Ebola in 2014, is hopeful of repeating the success with its coronavirus vaccine trials. The clinical tests are expected to begin next week, Gilbert said. She had last week told a leading magazine that her team is "80 percent sure" of developing the vaccine. Globally, the COVID-19 pandemic infected more than 1,900,000 persons by the time this report was published. The death toll climbed to 118,497. The worst-affected is the United States, where over 600,000 are infected and the death toll has crossed the 23,000-mark. Italy and Spain have recorded over 20,000 and more than 17,000 deaths, respectively. Source www.nytimes.com3124
- Indian researchers from JNCASR develops novel anti-microbial coatingIn Research Forum·April 2, 2020Bengaluru based Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), an autonomous institution under the Department of Science and Technology, has developed a one-step curable anti-microbial coating which, when coated on different surfaces such as textile, plastic and so on could kill a range of virus types including COVID 19. JNCASR is an autonomous institution under the Department of Science and Technology. According to the researchers, “till date, to the best of our knowledge, there is no covalent coating strategy which can kill all viruses, bacteria and fungi.” This covalent coating, the research paper about which has been accepted in the journal Applied Material and Interfaces, has been found to completely kill influenza virus as well as resistant pathogenic bacteria and fungi, including methicillin-resistant Staphylococcus aureus and fluconazole-resistant C. albicans spp. The molecules developed have an ability to chemically cross-link with different surfaces upon UV irradiation. Upon the formation of the coating, it has been shown to permeabilize the membranes of pathogens (i.e. bacteria) leading to their inactivation. Microbial attachment and their colony formation on different surfaces play a major role in the transmission of deadly infections in the community as well as healthcare settings. Keeping this in mind, an easy approach was developed to coat a wide range of substrates used in daily life as well as in clinical settings. Molecules were designed, keeping in mind their optimum solubility in a wide range of solvents (such as water, ethanol, chloroform). The coating can be fabricated on a variety of surfaces, and its ease and robustness eliminate the necessity of skilled personnel for procurement of the coating. Coronavirus, like influenza, is also an enveloped virus. Therefore, it is anticipated that the coating may inactivate SARS-CoV-2 upon contact and can help prevent contamination if coated on various surfaces. Considering the current outbreak, if shown to be active, the molecule can be synthesised in large scale through a CRO (Contract Research Organisation) and can be coated on various personal protective tools such as masks, gloves and gowns in collaboration with the private organisations. The molecules can also be coated on other medical devices and tools to avoid hospital-acquired or nosocomial infections. Currently, the frontline health workers are at the biggest risk currently. The molecules were then immobilised on different substrates such as cotton, polyurethane, polypropylene, polystyrene, etc., which construct majority of the objects we see around us. After coating, the surfaces were evaluated for their antibacterial, antifungal, and antiviral activity. References: BioSpectrum, https://www.biospectrumindia.com/news/58/16098/jncasr-develops-novel-anti-microbial-coating.html The Tribune, https://www.tribuneindia.com/news/nation/indian-researchers-develop-coating-that-kills-covid-642743150